data agree with mechanistic experiments in cell culture remarkably well. The results are the first demonstration that the dimerization of B1 and B2 subunits of GABA-B receptor is dynamically regulated. The findings also identify the interaction between 14-3-3-zeta and B1 as a potential therapeutic target, and indicate a method of specific manipulation of this interaction with appropriate peptide that holds promise for pain treatment. However, several presentation issues must be addressed to make this manuscript suitable for publication.
Main points:
1. The authors should clearly indicate that GABA-B receptor is a class C GPCR. Class C receptors are constitutive dimers, whereas the functional role of oligomerization of class A GPCRs is controversial. 2. The authors should also mention that, in contrast to the majority of class C GPCRs, where the dimer is stabilized by disulfide bonds between cysteine-rich domains (CRD), GABA-B receptor does not have CRD. This suggests that B1-B2 dimer may be more dynamic than the dimers of other class C receptors, possibly the only dynamic dimer in this sub-family.
Minor presentation issues 3. pp.10-11. As the data do not identify the site of 14-3-3 interaction with B1 subunit, the speculation regarding this site should be deleted. This does not in any way affect the validity of the findings. 4. Fig. 7 . Even though the same group of animals was apparently used, panels C-F should be bar graphs, as the connecting line creates false impression that the points represent a function. 5. Some editing is needed: p.3, "archetypical" should read "archetypal" or "prototypical'; "GABAB dysfunctioning" should read "GABAB dysfunction"; p. 4, "spinal cultured neurons" should read "cultured spinal neurons"; "both immunostaining were largely overlapping" should read "the immunostaining for both was largely overlapping"; p. 5, "to consider the possible dissociation" should be "to test possible dissociation"; "mismatch RNA" should be "control RNA"; p. 8, last paragraph, "radioactivity" should be " [35S] GTPγS binding"; p. 9, define mmRNA (one can guess that it stands for "mismatched" or control RNA, but the reader should not be left guessing); p. 10, "A set of evidence" should read "Several lines of evidence'; p. 11, "invalidation of 14-3-3" should read "knockdown of 14-3-3"; p. 12, "have been described" should be "have been detected" or "are localized"; p. 13, "it abolishes totally" should be "it totally abolishes"; throughout text, "in clinics" should be "in clinic"; etc. 6. Fig S1, panel A2 . Y-axis should be renamed (e.g., anti-sense RNA binding). Panels A2 and D should have the same Y-axis, as they show the same thing. 7. In all figures, "I Baclofen" should read "baclofen-induced current".
Referee #3
The authors tested the interesting hypothesis that heterodimerization of metabotropic GABAB receptors in the plasma membrane is regulated by an interacting protein (14-3-3) . This study appears to be based on the previous finding of the authors that heterodimeric GABAB receptors at the cell surface might be disrupted by chronic treatment of cultured spinal cord neurons with capsaicin (Laffray et al. 2007 , Eur. J. Neurosci. 25: 1402 ; the results of this study are however not mentioned and should be discussed in view of the finding of this manuscript). It is shown that overexpression of 14-3-3ζ -a cytosolic scaffolding protein known to interact with GABAB1 -in cultured spinal cord neurons leads to a segregation of GABAB1 and GABAB2 at the cell surface as tested by coimmunoprecipitation, colocalization immunocytochemistry and FLIM. Disrupting heterodimerization consequently impaired GABAB receptor function as shown by electrophysiological recordings and GTPγS binding experiments. The exciting finding of this study is that 14-3-3ζ is upregulated in a rat model of neuropathic pain, which then disrupts GABAB receptor heterodimers at the cell surface by binding to GABAB1, eventually resulting in diminished GABAB receptor function. siRNA-mediated knock-down of 14-3-3 or interfering with the GABAB1/14-3-3ζ interaction using a synthetic peptide restored heterodimerization of GABAB receptors and enhanced analgesic efficiency of the GABAB receptor agonist baclofen. If this effect is indeed mediated by disrupting the existing GABAB receptor heterodimers at the cell surface this would be a fascinating novel mechanism for regulating the activity of GABAB receptor function that may also be relevant to other receptors.
Although the authors made great effort to tackle the main questions with different methodological approaches there remain some key issues unresolved.
1. Mechanistically it is hard to comprehend how binding of 14-3-3ζ to GABAB1 disrupts heterodimerization of already assembled GABAB receptors. Previous studies suggest a low-affinity interaction of 14-3-3 ζ with GABAB1 as indicated by the lack of co-immunoprecipitation and the high amounts of 14-3-3 protein required to prevent binding of GABAB2 to GABAB1 in an in vitro overlay assay. Likewise, in the current study the authors used protein crosslinking prior to immunoprecipitation to be able to detect coprecipitation of GABAB1 with 14-3-3ζ. So how can a relatively small increase of 14-3-3ζ (30-40%) in the dorsal spinal cord after induction of neuropathic pain disrupt GABAB receptor heterodimers via a low affinity GABAB1 binding site that is, according to current knowledge, already occupied or masked by GABAB2?
2. The conclusion that 14-3-3ζ disrupts GABAB receptor heterodimerization at the cell surface appears to be not very well settled because it relies mainly on an indirect method, i. e. colocalization with marker proteins. Using an additional alternative method such as co-IP combined with cell surface biotinylation would be much more convincing and would further strengthen this important issue.
3. It is mentioned that after 14-3-3ζ-mediated disruption of GABAB receptor heterodimers GABAB2 becomes instable and is degraded. This is an important point and needs to be addressed quantitatively. What is the reduction of GABAB2 after upregulation of 14-3-3ζ and can the potential downregulation of GABAB2 be prevented by inhibition of lysosomal degradation? 4. It is not clear from the study to what extend 14-3-3ζ influences heterodimerization under normal "control" conditions. Is there already equilibrium of heterodimers and GABAB1 associated with 14-3-3ζ at the cell surface with normal expression levels of 14-3-3ζ? The study needs to be supplemented with experiments analyzing the effects of 14-3-3ζ siRNA and competing peptide on the heterodimerization of GABAB receptors under "normal conditions".
5. The authors state that 14-3-3ζ act postsynaptically and thus affects heterodimerization of GABAB1b containing receptors. In spinal cord neurons GABAB1a is much more abundant than GABAB1b as can clearly be judged from the western blots shown (Fig. 5, C1 ). The 35S-GTPγS binding experiments revealed a more than 60% reduction of binding after upregulation of 14-3-3 ζ. This is in stark contrast to the comparable low abundance of GABAB1b. In addition, the IP experiment shown in Fig 5 C1 clearly demonstrates a similar reduction of bands corresponding to GABAB1a and GABAB1b contradicting the statement of the authors. The authors may want to directly test the effect after upregulation of 14-3-3 ζ on GABAB1a (suitable antibodies are commercial available, e.g. Alpha Diagnostic).
6. It is not clear why the authors transiently overexpressed GABAB1 and GABAB2 in spinal cord neurons for analyzing the effect of 14-3-3 ζ. What is the effect of overexpression of 14-3-3 ζ on endogenous GABAB receptors expressed in spinal cord neurons? These experiments should be repeated in untransfected neurons and with antibodies detecting native GABAB1 and GABAB2 receptors.
6. The data shown in Fig. S7B -D is not sufficient to exclude an impact of trafficking on the observed effects.
7. Supplemental results, page1, Fig S2: A positive control for colocalization of 14-3-3ζ with postsynaptic markers is missing.
8. Supplemental experimental procedures, page 8: The details for crosslinking before immunoprecipitation need to be provided.
9. Discussion, page 12: The authors state that overexpression of 14-3-3ζ partially disrupts GABAB receptor heterodimerization but completely abolishes GABAB receptor signaling. However, there is still considerable 35S-GTPγS binding left after induction of neuropathic pain in the dorsal horn contradicting this statement.
10. Discussion, page 11, last para.: "since there is no pain-associated decrease in GABAB subunit expression (Engle et al., 2006) , nor receptor loss by endocytosis (Laffray et al., 2007) . This statement is not correct. Downregulation of GABAB receptor subunits has been reported in rat models of diabetic neuropathy (Wang et al., 2011, Neurosci. Lett.490:112) and spinal nerve ligation (same method as used in this study; Wu et al. 2011, Neuroimmunomodulation 18:150) . In addition, the reference of Laffray et al is not adequate because no animal pain model was used in that study.
11. Fig. 7C -F: Presenting the data in bar graphs would be more adequate.
12. It needs to be described in detail how western blots were quantified (which detection system? Chemoluminescence? Fluorescence?) and how linearity of signal was warranted.
13. 
Reviewer 1
We thank the reviewer for his/her very positive comments on the manuscript, and for the overall support to our study.
1. We fully agree with the reviewer (see also Reviewer 3) that it is not easy to understand how the increase of 14-3-3 expression disrupts the already associated heterodimer. We also acknowledge that we did not attempt, in our study, to clearly unravel this mechanism of action which would require a dedicated study with specific expertise. Nevertheless, all our data are consistent with dedimerization. To cause dedimerization, 14-3-3 needs to interfere with the coiled-coil domain in the intracellular C-terminus of the GABAB receptor. This interaction can be facilitated by some instability of the receptor. Indeed, recent studies point out that GPCR are not as stable as initially believed, especially when in a ligand-free state. Moreover, beside the intracellular part, the extracellular domain plays also an important role in the overall stability, and dynamics, of the GPCRs. We can therefore consider two mechanisms that may account for B1/B2 uncoupling.
• As reminded by the Reviewer 2, the GABAB receptor is a peculiar class C receptor, since no cys-rich region exists in the extracellular domain, in particular in the ligand-binding domain (Galvez et al., 1999, J. Biol. Chem.; Kniazeff et al., 2011, Pharmacol. Therap.) . These cysteine residues are responsible for the stability of the extracellular domains, and hence of the receptor dimer (Bouvier, 2001, Nat. Rev. Neurosci.) . The consequence of the absence of cys-rich extracellular domains is that the extracellular interaction between the subunits might be rather weak, and the GABAB dimer much more unstable than other class C GPCRs.
• GPCR conformation may be highly dynamic and domain coupling is altered by intrinsic disorder of the receptor. A very recent review emphasizes that this disorder, underlying permanent rearrangements of the receptor, is highly increased in ligand-free states (Unal and Karnik, 2011, TIPS) . Moreover, very subtle changes in the receptor conformation are likely to modify domain coupling and receptor activation (Rasmussen et al., 2011, Nature) . Taken together, these data suggest that GPCRs are highly dynamic molecular scaffolds. It is thus conceivable that, taking advantage of such permanent rearrangements, 14-3-3 binds to accessible sequence in the B1 C-ter, and triggers more profound conformational changes that finally result in a complete dedimerization of the receptor. It is also possible that additional partner proteins are recruited (as we already hypothesized in the manuscript, Discussion, end of § "GABAB dimer is impaired by 14-3-3z interacting protein") and increase the instability of the receptor, thus facilitating 14-3-3 binding. Such additional proteins may also contribute to the completion of the dedimerization initiated by 14-3-3.
Given these data, a sentence has been added in the Discussion (p11, "Importantly, the GABAB receptor is likely to be more dynamic than other receptor in the class C sub-family since it lacks cysteine-rich domain in the extracellular part (Kniazeff et al., 2011) . This might make the GABAB more susceptible to undergo conformational changes upon partner protein interaction.").
2. We have added a statement referring to our previous work (Laffray et al, 2007) at the beginning of the Discussion section ("Therefore, the present study is in line with, and further extend our previous report that chronic activation with capsaicin of an organotypic culture model induces a dissociation of the GABAB receptor, and a loss of GABAB activation (Laffray et al, 2007) ."). The present results go far beyond this previous report by proposing a causal agent that accounts for GABAB dedimerization, and by pointing out that such dedimerization occurs in a pathophysiological context.
3. In Fig. S4D2 , we reported the 14-3-3 mRNA level in dorsal root ganglia. This mRNA level does not change after siRNA injection. Our interpretation is that the DRGs are not affected by intrathecal injections following catheter implantation. This result is an agreement with our previous finding (Fossat et al., J. Neurosci. 2010) showing no diffusion to the DRGs of intrathecally injected antisense molecules.
4. The reviewer is right that anti-14-3-3 siRNA does not induce any effect when injected alone, prior to Baclofen treatment. We do not have a straightforward explanation for this effect but we consider that it relies on the greater specificity of action of the peptides as compared to the siRNA. The competing peptides that have been designed specifically target the interaction site with B1 and do not prevent 14-3-3 proteins to bind most of their other partners, as exemplified for Raf (Fig. S6E ). This shows that the interaction between B1 coiled-coil domain and 14-3-3z is distinct from the wellcharacterized interaction mediated by the two canonical mode I (RSXpSXP) and mode II (RXXXpSXP) binding motifs. Instead, B1/14-3-3z interaction appears characteristic of the mode III binding (Coblitz et al., FEBS Letter, 2006) . As compared to siRNA that knocks down all 14-3-3 proteins, our competing peptides target only mode III binding partners, among more than 300 possible partners identified so far (Pozuelo Rubio et al., Biochemical J., 2004) . This interesting feature is likely to confer higher selectivity to the peptides, whereby avoiding unwanted side-effects. Indeed, the injected pVEC-B1R (922-930) had anti-nociceptive properties per se in neuropathic conditions.
Reviewer 2
We thank this reviewer for the very positive comments and for his/her interest in our finding.
1. We have now made clear that the GABAB is a class C GPCR that is constitutively dimeric. We added sentences in that sense at the beginning of §1 in the Discussion.
2. We followed the very relevant suggestion of the reviewer. We must acknowledge that we are very grateful to the reviewer for this comment that helped us to discuss the possible mechanisms allowing 14-3-3 to disrupt the GABAB dimer. We have inserted the following statement at the end of Discussion, §1 : "Importantly, the GABAB receptor is likely to be more dynamic than other receptor in the class C sub-family since it lacks cysteine-rich domain in the extracellular part (Kniazeff et al., EMBO J, 2011) . This might make the GABAB more susceptible to undergo conformational changes upon partner protein interaction.".
3. Apart using the B1 ASA mutant, it is true that there is no further data to precisely identify the site of interaction between B1 and 143-3, we deleted the statement about the interaction at the coiled-coil domain (Discussion, pp 10-11, "In agreement with a previous report {Couve, 2001 #1134}, GABAB de-dimerization might be thus triggered by 14-3-3z-interaction at the coil-coiled domain.") as requested by the reviewer.
4. The figures 7C-F have been replaced by bar graphs.
5. All editing corrections have been made.
6. The Y axis in Figure S1A2 has been renamed (" . The Y axis in Fig.  S1D has been also renamed accordingly.
7. Baclofen-induced current have been written instead of I Baclofen in Figure 4 and new Figure S7 .
Reviewer 3
We are grateful to this reviewer for his/her careful reading of our manuscript and for the constructive comments and criticisms. Actually, these comments have forced us to reconsider some of our statements that were inadequate. We believe that this revision resulted in expanding the impact of our findings.
As stated by the reviewer, this study is the continuation of a previous report from our group showing that the GABAB receptor association was impaired after chronic stimulation of a culture model (Laffray et al. 2007 ). We are now clearly referred to this paper in the first paragraph of the discussion ("Therefore, the present study is in line with, and further extend our previous report that chronic activation with capsaicin of an organotypic culture model induces a dissociation of the GABAB receptor, and a loss of GABAB activation (Laffray et al, 2007) .").
1. We fully agree with the reviewer (see also Reviewer 1) that it is not easy to understand how the increase of 14-3-3 expression disrupts the already associated heterodimer. We also acknowledge that we did not attempt, in our study, to clearly unravel this mechanism of action which would require a dedicated study with specific expertise. Nevertheless, all our data are consistent with dedimerization. To cause dedimerization, 14-3-3 needs to interfere with the coiled-coil domain in the intracellular C-terminus of the GABAB receptor. This interaction can be facilitated by some instability of the receptor. Indeed, recent studies point out that GPCR are not as stable as initially believed, especially when in a ligand-free state. Moreover, beside the intracellular part, the extracellular domain plays also an important role in the overall stability, and dynamics, of the GPCRs. We can therefore consider two mechanisms that may account for B1/B2 uncoupling.
2. To answer the reviewer's concern, we performed a double immunoprecipitation experiment according to a protocol derived from the original method published by (Holman and Henley, J. Neurosci. Meth., 2007) . The result shows that the association between B1 and B2 is impaired at the cell membrane after overexpression of 14-3-3. The gel is presented on Fig. 3B . We added the description of this new experiment in Results, §2, "In an additional experiment, COS cell transfected with B1b and B2, (Holman & Henley, 200) . Western blotting for the B2 subunit revealed that B1b/B2 association was lost at the cell membrane after 14-3-3z overexpression (Fig. 3B) .". Our study provides several lines of evidence, either direct or indirect, indicating a dissociation of the dimer at the plasma membrane upon 14-3-3z overexpression. We are summarizing these data in the following.
were treated with sulfo-NHS-SS-biotin. Total cell extracts were then submitted to co-immunoprecipitation of B1b and B2 and the membrane fraction was retrieved by immunoprecipitation with agarose-conjugated streptavidin according to a protocol derived from Holman and Henley
Indirect evidence: 1. Association between B1 and 14-3-3z in membrane domains as seen with light and electron microscopy. 2. Lack of B1/14-3-3z interaction in the endoplasmic reticulum (Brock et al., Mol Biol. Cell, 2005) . 3. Degradation of B2 subunit in COS cell upon 14-3-3z overexpression, suggesting that this subunit is released from the dimer, thus becoming unstable. 4. Inhibition of dedimerization when the dimer is not trafficked toward the plasma membrane upon Brefeldine treatment.
Direct evidence: 1. Regionalized FLIM analysis showing a decrease of B1/B2 interaction at the membrane, but not in other subcellular compartments, indicating that the dimer is not dissociated in the endoplasmic reticulum nor in the Golgi. 2. Loss of membrane association between B1 and B2 as seen with the double immunoprecipitation experiment.
Taken together, these data strongly suggest that dedimerization does occur at the plasma membrane.
3. We have measured possible GABAB2 degradation in COS cells after 14-3-3 overexpression, in the presence or in the absence of chloroquine (Chen et al., 2011, Cell & Bioscience) , a lysosomotropic agent that prevents lysosomal acidification and inhibits lysosomal enzymatic activity. We found a significant decrease of B2 staining with Western Blot after 14-3-3 overexpression. This decrease is abolished when COS cells are treated with Chloroquine, thus indicating that 14-3-3-induced loss of B2 staining is due to lysosomal degradation. These new results are now illustrated in Figure S3E and mentioned in Results ( §2, para 2, "Inhibition of lysosomal activity increases the amount of B2 in protein extracts from COS cells after 14-3-3z overexpression (Fig. S3E) . This indicates that B2 subunit is trafficked toward the lysosomes for degradation after 14-3-3z-induced heterodimer dissociation."). We also did some treatments with MG132, a cell-permeable inhibitor of the proteasome, and the loss of B2 staining did not revert to normal (data not shown). This shows that B2 is degraded by lysosomes, not proteasome. In contrast, no effect is found for the B1 staining. Therefore, B1 and B2 staining show differential changes upon 14-3-3 overexpression. This new set of data strengthens the view that 14-3-3 indeed dedimerizes the receptor, thus releasing the B2 subunit from the dissociated dimer. Moreover, this is consistent with the reduced stability of B2 when expressed alone (Galvez et al., 2001 ), and we now refer to this study in the Results section ( §2, para 2, "The loss of B2 subunit at the membrane where 14-3-3/B1 complexes are formed is consistent with the decreased stability of B2 alone at the membrane in cultured cells (Galvez et al., 2001) .").
4. According to the reviewer's suggestion, we performed injections of siRNA and/or peptide in groups of Sham rats (n = 5) in order to check for the influence of 14-3-3 under normal conditions. We analyzed such an effect with immunohistochemistry (colocalization, siRNA) and immunoprecipitation (interaction, siRNA and peptide). The data are presented in Fig. 5B and C1 and briefly mentioned in Results, §4. The micrographs corresponding to the new colocalization study in Sham rats after siRNA injections are not shown to avoid overloading the figure 5. Instead, a new graph (Fig. 5B) summarizes the quantitative data from Sham and SNL. The Western Blot obtained after immunoprecipitation in Sham rats is also presented in Fig. 5C1 , together with its quantification (one histogram combining data from SNL and Sham).
This set of new data confirms the lack of 14-3-3 effect on B1/B2 association when the chaperone protein is expressed only at low levels. It also suggests low level of B1/14-3-3 association in control conditions, which is in agreement with the results of the B1/14-3-3 co-immunoprecipitation presented in Fig. 5C2 . Indeed, it supports the hypothesis that overexpression is required for an effect of 14-3-3 on the GABAB heterodimer (cf Results, §4, and Discussion, end of p11).
5. The reviewer is perfectly right. The observation of the neuropathy-induced decrease of both B1a and B1b staining in the co-Ip of the Figure 4 was very relevant. This concern raised by the reviewer prompted us to reconsider our interpretation that 14-3-3 interacts mainly with B1b. We first explored the FRET efficiency between B1a and B2, with or without 14-3-3 overexpression in neuronal cell cultures. The effect of 14-3-3 was similar to what happens for the B1b/B2 dimer and the FRET efficiency was significantly reduced after 14-3-3 overexpression (new Fig. S3F ). Actually, this is quite expected since the C-termini of both types of heterodimer, comprising the coiled-coil domain, are identical. This result supports a similar effect of 14-3-3 on both types of heterodimers. It also strengthens our previous findings by expanding the dedimerizing effect of 14-3-3 to the other type of GABAB dimer. Importantly, FRET was not altered when overexpressing another 14-3-3 isoform (Fig. S7B) , indicating the specificity of action of 14-3-3z. Since B1a is the most abundant splice variant of the B1 subunit in the pre-synaptic compartment, we strived to repeat the double-labeling experiments with synaptic markers. Moreover, we compared the results obtained in Sham and SNL rats (new Fig. S2 ). To detect 14-3-3 with the best sensitivity, we applied a tyramide-based protocol for immunohistochemistry (Landry et al., J. Comp. Neurol., 2004) . We found that the colocalization with presynaptic markers remained weak in Sham rats but increased in SNL rats. In contrast, 14-3-3 was highly co-expressed with the postsynaptic marker, PSD95, even though a slight increase was also noticed in SNL rats. The results are shown in Fig.  S2A and quantified in Fig S2B . Therefore, we now consider that 14-3-3 can dedimerize both B1a/B2 and B1b/B2 dimers in SNL rats. In agreement, 14-3-3 was found both in pre-and post-synaptic compartments in SNL rats, and we corrected our previous statements throughout the manuscript. It explains why both the intensity of B1a and B1b staining was decreased similarly after B1/B2 co-IP in vivo. It also provides a hypothesis for the strong decrease of GTP binding seen in the dorsal horn of SNL rats.
6. We chose to overexpress B1 and B2 in cultured neurons mainly to make it possible to perform FRET experiments with fluorochrome-tagged GABAB subunits. However, the reviewer is right that the colocalization study should be repeated on native proteins in culture. We did these experiments in spinal cultures with an anti-B1 antibody that does not discriminate between B1a and B1b. We found results that are very similar to those obtained after GABAB subunits overexpression (new Fig.  S3A1-3) , thus validating the results described in Fig. 2A -C. The manuscript has been amended accordingly (Results, §2, end of para 1: "In addition, we demonstrated that the same changes occur in the colocalization of endogenous overexpression in cultured spinal neurons (Fig. S3A1-A3 )"). 6 bis . We have added some new experiments to rule out an impact of trafficking on the observed results. Our previous attempt relied only on the comparison of cytoplasm/membrane staining intensity ratio measured from tissue sections. Our new experiments rely on data from cell cultures overexpressing 14-3-3. By this mean, we address the issue of 14-3-3 impact on GABAB trafficking more directly. Because 14-3-3 binds exclusively to B1, and not to B2, we focused on B1 trafficking only. First, we used neuronal cell cultures to perform double-labeling detections of endogenous B1 and subcellular markers including Mannosidase II, Calreticulin, and Rab5. The two former markers have been already used in our regionalized FRET analysis to identify the Golgi and ER, respectively. Rab5 is a classical marker of early endosomes. As in the new Figure 5 (see §4 of the comments to Reviewer 3), we have chosen not to present the micrographs but rather the histogram summarizing the quantitative data (new Fig. S8D ). Of course, micrographs are available upon request if needed. The percentage of colocalization between B1 and subcellular marker staining was analyzed using the Metamorph software. No differences were notices between cells transfected with 14-3-3-expressing construct and control GFP. Second, we used COS cells to carry out biochemical analysis of B1 content after co-transfection of constructs expressing B1, B2, and 14-3-3. We measured B1 staining in the total protein extract and in the membrane fraction isolated after surface biotinylation. We expressed the results as the ratio between cytoplasm/membrane staining intensity. Results are shown in Fig. S8E . No difference was noticed between COS cells overexpressing, GFP or 14-3-3. 7. A positive control for 14-3-3 colocalization with a post-synaptic marker (PSD95) has been included. Moreover, a comparison has been made between Sham and SNL rats (new Fig. S2A g and  h) . The results have been quantified (new Fig. S2B ). Indeed, 14-3-3 does colocalize with PSD95 in Sham rats and even more in SNL rats (see also §5 of the present response to Reviewer 3). The point we want to make is that although there is still some GABAB activation remaining (exemplified with FLIM analysis and GTP assay), the down-stream signaling becomes too weak to drive efficient changes of cellular activity (Kir recordings) and behavior (von Frey testing).
10. The wrong statements have been replaced in the discussion. The recent paper (Wu et al., 2011) mentioned by the referee is now cited. ("The dissociation may be a pivotal mechanism that limits GABAB activation in neuropathic conditions. It may act jointly with other mechanisms, e.g. possible down-regulation of GABAB subunits (Wu et al., 2011) ."). We must notice however that, in the present sudy, we did not detect down-regulation of GABAB subunit transcription (see Fig. S8A1 -A2).
11. Fig. 7C -F is now presented as bar graphs as requested.
12. For Western Blot, the signal was revealed with enhanced chemiluminescence. The quantification was performed on a Syngene system for which the linearity has been checked. The Syngene system and the GeneTools analysis software, that is used for quantification, are made available in our Biochemistry facility for Neuroscience. We have added a description of this method in the Supplemental Material and Method, § Immunoprecipitation on spinal cord samples: "For Western Blot, the density of bands was quantitated by densitometry using a Syngene machine (ChemiGenius 2XE model, Synoptics Ltd, Cambridge, UK) . For immunoprecipitation, immunoblots were semiquantified by normalizing the IP band density to that of the lysate band. The linearity of the data was determined by the square of the correlation coefficient. To calibrate the Syngene system, the signal intensities have been plotted against the amount of actin protein loaded on gel. The images were analysed using GeneTools analysis software (Syngene) . As compared to X-Ray films, the CCD captured images have a better linearity and a greater dynamic range which make the data more quantitative.".
13. The legends have been amended according to the reviewer's comments (Fig. 2, Fig. 3, Fig. 4 , new Fig. S7 ).
14. The Brefeldin experiment has been performed according to a protocol derived from Wisco and Anderson (2003, J. Cell Biol.) . The role of Brefeldin has been made clearer at the end of Results, §2: "When membrane targeting of the B1/B2 dimer is prevented with Brefeldin A, the GABAB dimeric state was not altered, as monitored with co-IP in COS cells. This suggests that dedimerization occurs only when GABAB heterodimers are targeted to the plasma membrane, thus confirming that 14-3-3z disrupts already formed heterodimers at the cell surface." Actually, Brefeldin does not restore the dimeric state but rather prevents the membrane targeting of GABAB receptors newly formed after transfection. Therefore, if GABAB is detected as dimers after Brefeldin treatment upon 14-3-3 overexpression, this suggests that the receptor remains as a dimer as long as it does not reach
